Show simple item record

dc.contributor.authorOrsolini, Laura
dc.contributor.authorChiappini, Stefania
dc.contributor.authorVolpe, Umberto
dc.contributor.authorDe Berardis, Domenico
dc.contributor.authorLatini, Roberto
dc.contributor.authorPapanti, Gabriele Duccio
dc.contributor.authorCorkery, John
dc.date.accessioned2019-08-29T02:08:11Z
dc.date.available2019-08-29T02:08:11Z
dc.date.issued2019-08-23
dc.identifier.citationOrsolini , L , Chiappini , S , Volpe , U , De Berardis , D , Latini , R , Papanti , G D & Corkery , J 2019 , ' Use of Medicinal Cannabis and Synthetic Cannabinoids in Posttraumatic Stress Disorder (PTSD): a systematic review ' , Medicina , vol. 55 , no. 9 , 525 . https://doi.org/10.3390/medicina55090525
dc.identifier.issn1010-660X
dc.identifier.urihttp://hdl.handle.net/2299/21634
dc.description.abstractBackground and Objectives: Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives for the treatment of this condition. The present paper aims to evaluate the clinical and therapeutic potentials of medical cannabis and synthetic cannabinoids in treating PTSD patients. Methods: A systematic electronic search was performed, including all papers published up to May 2019, using the following keywords (((cannabis[Title/Abstract]) OR (synthetic cannabinoids [Title/Abstract])) AND ((PTSD[Title/Abstract]) OR (Posttraumatic stress disorder[Title/Abstract]))) for the topics ‘Cannabis’, ‘Synthetic Cannabinoids’, ‘PTSD’, and MESH terms, on the PubMed, Cochrane Library, and Web of Science online databases. For data gathering purposes, PRISMA guidelines were followed. Results were organized into two groups, considering cannabis and synthetic cannabinoids as different therapeutic approaches for PTSD. Results: Present data show that cannabis and synthetic cannabinoids, both acting on the endocannabinoids system, may have a potential therapeutic use for improving PTSD symptoms, e.g., reducing anxiety, modulating memory-related processes, and improving sleep. Conclusions: Even though the current literature suggests that cannabis and synthetic cannabinoids may have a role in the treatment of PTSD, there is currently limited evidence regarding their safety and efficacy. Therefore, additional research is needed in order to better understand the effectiveness and therapeutic usage of these drug classes and monitor their safety.en
dc.format.extent14
dc.format.extent408641
dc.language.isoeng
dc.relation.ispartofMedicina
dc.subjectCBD
dc.subjectCannabinoids
dc.subjectCannabis
dc.subjectEndocannabinoid system
dc.subjectPTSD
dc.subjectSynthetic cannabinoids
dc.subjectTrauma
dc.subjectMedicine(all)
dc.titleUse of Medicinal Cannabis and Synthetic Cannabinoids in Posttraumatic Stress Disorder (PTSD): a systematic reviewen
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85071772228&partnerID=8YFLogxK
rioxxterms.versionofrecord10.3390/medicina55090525
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record